Dallas, TX – August 7, 2020 – — Puration, Inc. (OTC PINK: PURA) today announced plans for a formal declaration of a dividend distribution this coming Monday, August 10, 2020. The dividend declaration is expected to be announced the following day, on Tuesday, August 7, 2020. The plan is for the dividend distribution date of record or the day on which a shareholder must own stock to be eligible for the dividend to promptly follow the declaration date. The declaration date is subject to regulatory approval and the specific date will be released accordingly. The plan is also to pay the dividend promptly. The payment execution is subject to the payment process which involves the transfer agent(s) for the distributed stock and the broker network.
The planned dividend distribution to PURA shareholders results from the recent sale of PURA’s cannabis cultivation operation to PAO Group, Inc. (OTC PINK: PAOG).
The cannabis cultivation operation was sold last week in exchange for PAOG common stock. The stock is slated to be distributed to PURA shareholders in a dividend distribution. The planned distribution ratio is 1 for 1. Accordingly, PURA shareholders will receive one share of PAOG stock in exchange for every PURA share held.
For more information on Puration, visit http://www.purationinc.com
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.